Short-term and long-term modulation of gene expression by antisense therapeutics

Current Opinion in Biotechnology

Volumn 13, Issue 5, 2002, Pages 468-472

  Sazani, Peter ^a,b   Vacek, Marla M ^b   Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; RIBONUCLEASE H; RNA; VIRUS VECTOR;

CHIMERA; GENE CONTROL; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; REVIEW; RNA SPLICING; TRANSLATION REGULATION;

EID: 18744366905     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00366-X     Document Type: Review

References (39)

1. Krainer A. Hames B., Glover D. Eukaryotic mRNA Processing. 1997;Oxford University Press, New York.
2. Herdewijn P. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev. 10:2000;297-310.
3. Micklefield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med Chem. 8:2001;1157-1179.
4. Mercatante D., Sazani P., Kole R. Modification of alternative splicing pathways as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets. 1:2001;211-230.
5. Manoharan M. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta. 1489:1999;117-130.
6. Kole R., Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther. 3:2001;229-234.
7. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1489:1999;53-68.
8. Obika S., Uneda T., Sugimoto T., Nanbu D., Minami T., Doi T., Imanishi T. 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg Med Chem. 9:2001;1001-1011.
9. Torigoe H., Hari Y., Sekiguchi M., Obika S., Imanishi T. 2′-O,4′-C-methylene bridged nucleic acid modification promotes pyrimidine motif triplex DNA formation at physiological pH. Thermodynamic and kinetic studies. J Biol Chem. 276:2001;2354-2360.
10. Morita K., Hasegawa C., Kaneko M., Tsutsumi S., Sone J., Ishikawa T., Imanishi T., Koizumi M. 2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett. 12:2002;73-76.
11. Gryaznov S.M. Oligonucleotide N3′→P5′ phosphoramidates as potential therapeutic agents. Biochim Biophys Acta. 1489:1999;131-140.
12. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta. 1489:1999;141-158.
13. Elayadi A.N., Corey D.R. Application of PNA and LNA oligomers to chemotherapy. Curr Opin Investig Drugs. 2:2001;558-561.
14. Declercq R., Van Aerschot A., Read R.J., Herdewijn P., Van Meervelt L. Crystal structure of double helical hexitol nucleic acids. J Am Chem Soc. 124:2002;928-933.
15. Kole R., Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther. 3:2001;229-234.
16. Schwartz E., Benz E. Hoffman R., Benz E., Shattil S., Furie B., Cohen H., Silberstein L., McGlave P. Thalassemia Syndromes. 1995;Churchill Livingston, New York.
17. Lacerra G., Sierakowska H., Carestia C., Fucharoen S., Summerton J., Weller D., Kole R. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA. 97:2000;9591-9596. Morpholino antisense oligonucleotides corrected aberrant splicing of β-globin pre-mRNA in hematopoietic progenitor cells from thalassemic patients and increased production of functional hemoglobin.
18. Mercatante D.R., Bortner C.D., Cidlowski J.A., Kole R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J Biol Chem. 276:2001;16411-16417. Antisense oligonucleotides that shift splicing of bcl-x pre-mRNA from the anti- to the pro-apoptotic splice variant induced apoptosis in a prostate cancer cell line.
19. Kalbfuss B., Mabon S.A., Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem. 276:2001;42986-42993.
20. Lim S.R., Hertel K.J. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem. 276:2001;45476-45483.
21. Sazani P., Kang S.H., Maier M.A., Wei C., Dillman J., Summerton J., Manoharan M., Kole R. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29:2001;3965-3974.
22. Faria M., Spiller D.G., Dubertret C., Nelson J.S., White M.R., Scherman D., Helene C., Giovannangeli C. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat Biotechnol. 19:2001;40-44.
23. Heasman J. Morpholino oligos: making sense of antisense? Dev Biol. 243:2002;209-214.
24. Zhong T.P., Childs S., Leu J.P., Fishman M.C. Gridlock signalling pathway fashions the first embryonic artery. Nature. 414:2001;216-220.
25. Wang H., Wang S., Nan L., Yu D., Agrawal S., Zhang R. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Int J Oncol. 20:2002;745-752.
26. Isis Pharmaceuticals on World Wide Web URL: http://www.isispharmaceuticals.com/pipeline.htm .
27. Arzumanov A., Walsh A.P., Rajwanshi V.K., Kumar R., Wengel J., Gait M.J. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry. 40:2001;14645-14654.
28. Gorman L., Mercatante D.R., Kole R. Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J Biol Chem. 275:2000;35914-35919.
29. Liu X., Jiang Q., Mansfield S.G., Puttaraju M., Zhang Y., Zhou W., Cohn J.A., Garcia-Blanco M.A., Mitchell L.G., Engelhardt J.F. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol. 20:2002;47-52. Reprogramming splicing of pre-mRNA by spliceosome-mediated RNA trans-splicing corrected endogenous mutant CFTR pre-mRNA in cystic fibrosis airway epithelia and partially restored CFTR-mediated chloride transport.
30. Abounader R., Lal B., Luddy C., Koe G., Davidson B., Rosen E.M., Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16:2002;108-110.
31. Carr J.M., Calvert J.K., Kumar R., Burrel C.J., Li P. Effect of deletion and the site of insertion in double copy anti-tat retroviral vectors: viral titres and production of anti-tat mRNA. Arch Virol. 146:2001;2191-2200.
32. Mautino M.R., Morgan R.A. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 9:2002;421-431.
33. Fahmy R.G., Khachigian L.M. Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. J Cell Biochem. 84:2002;575-582.
34. Finegold A.A., Perez F.M., Iadarola M.J. In vivo control of NMDA receptor transcript level in motoneurons by viral transduction of a short antisense gene. Brain Res Mol Brain Res. 90:2001;17-25.
35. Quan S., Yang L., Abraham N.G., Kappas A. Regulation of human heme oxygenase in endothelial cells by using sense and antisense retroviral constructs. Proc Natl Acad Sci USA. 98:2001;12203-12208.
36. Samani A.A., Fallavollita L., Jaalouk D.E., Galipeau J., Brodt P. Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. Hum Gene Ther. 12:2001;1969-1977.
37. Pachori A.S., Huentelman M.J., Francis S.C., Gelband C.H., Katovich M.J., Raizada M.K. The future of hypertension therapy: sense, antisense, or nonsense? Hypertension. 37:2001;357-364.
38. Pachori A.S., Numan M.T., Ferrario C.M., Diz D.M., Raizada M.K., Katovich M.J. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension. 39:2002;969-975. This study demonstrates that a single intracardiac administration of a retroviral vector containing angiotensin II type I receptor antisense in the neonatal rat resulted in long-term expression of the antisense transgene in various cardiovascular tissues, causing a significant attenuation of cardiac hypertrophy.
39. Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R: High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 2002, in press.